Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Operating Expenses: 2023-2025

Historic Operating Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $15.8 million.

  • Compass Therapeutics' Operating Expenses rose 29.23% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.4 million, marking a year-over-year increase of 26.87%. This contributed to the annual value of $57.5 million for FY2024, which is 14.12% up from last year.
  • Latest data reveals that Compass Therapeutics reported Operating Expenses of $15.8 million as of Q3 2025, which was down 24.92% from $21.1 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Operating Expenses peaked at $21.1 million during Q2 2025, and registered a low of $9.7 million during Q1 2023.
  • Over the past 3 years, Compass Therapeutics' median Operating Expenses value was $15.4 million (recorded in 2023), while the average stood at $14.8 million.
  • Data for Compass Therapeutics' Operating Expenses shows a peak YoY surged of 40.69% (in 2025) over the last 5 years.
  • Compass Therapeutics' Operating Expenses (Quarterly) stood at $15.4 million in 2023, then increased by 7.67% to $16.6 million in 2024, then grew by 29.23% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $21.1 million for Q2 2025, and $18.0 million during Q1 2025.